Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 5Active not recruiting 4Recruiting 3Terminated 1Available 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Plasma cell 4

Conditions

Multiple Myeloma 4Recurrence 1

Interventions

pembrolizumab 439Carboplatin 322Nivolumab 298Cyclophosphamide 286Specimen Handling 271Magnetic Resonance Spectroscopy 259Cisplatin 250Paclitaxel 249Radiotherapy 230Dexamethasone 184Biopsy 182Gemcitabine 180durvalumab 171atezolizumab 152Doxorubicin 141Rituximab 138Lenalidomide 136Ipilimumab 134Docetaxel 132Bevacizumab 132Radiation 121Capecitabine 120Oxaliplatin 116Etoposide 116Radiosurgery 113Fluorouracil 112Pemetrexed 109fludarabine 106venetoclax 102Prednisone 97

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Active not recruiting × idecabtagene vicleucel × Clear all
NCT05393804 2026-04-02

A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
24 enrolled
Plasma cell

Multiple Myeloma

NCT06045806 2026-03-05

KarMMa-9

Celgene

Phase 3 Active not recruiting
79 enrolled
Plasma cell

Multiple Myeloma

NCT06154902 2023-12-04

ABE-DESCART

Bristol-Myers Squibb

Active not recruiting
350 enrolled
Plasma cell

Multiple Myeloma

NCT03651128 2022-12-15

KarMMa-3

Celgene

Phase 3 Active not recruiting
381 enrolled
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡